The phosphate binder is now available as 750mg and 1g sachets of oral powder for use in patients who have difficulty with the tablet formulation.
The powder is licensed for the same indications as the Fosrenol chewable tablet: treatment of hyperphosphataemia in patients with chronic kidney disease (CKD) on haemodialysis or peritoneal dialysis. It can also be used in patients with CKD who are not on dialysis but have a serum phosphate level of 1.78mmol/l or more despite a low phosphate diet.
Adjustable dose regimen
The dose of Fosrenol should be titrated every 2–3 weeks until an acceptable serum phosphate level is achieved. Control is usually achieved at a total daily dose of 1.5–3g.
The powder should be mixed with a small quantity of soft food and consumed within 15 minutes. Patients should not attempt to dissolve the powder in liquid as it is insoluble.
View Fosrenol Oral Powder drug record
Further information: Shire Pharmaceuticals Ltd